Weekend off

Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis. N= 2497. No difference in PFS or OS #mmsm Fieke Hoff Gurbakhash Kaur Rahul Banerjee, MD, FACP Blood Cancer Journal nature.com/articles/s4140…

In NDMM, how does KRd compare to VRd regarding efficacy endpoints? Happy to share our new meta-analysis just published in AmericanJournalofHematology: doi.org/10.1002/ajh.27…. KRd-treated pts showed higher odds of achieving MRD negativity and CR/sCR compared to VRd-treated pts, while ORR,

#IDAHOBIT Against all types of discrimination.

Out in Blood Cancer Journal! Years of collaborations between Sylvester Comprehensive Cancer Center University of Miami Università di Torino Università degli Studi di Milano Istituto Tumori and founded by Fondazione AIRC per la ricerca sul cancro – Using #WGS and #Flowcytometry to investigate the genomic and immune factors that contribute to resistance to anti-CD38 MoAbs in #RRMM #mmsm

Reputo veramente disgustoso e imbarazzante il trattamento che continua a essere dato in diretta Rai nei confronti di una ragazzina di 19 anni alla quale pare non sia concesso dire che gareggiare alle Olimpiadi sia stata la gioia più bella della sua vita, solo perché ha chiuso 4ª.

Waiting for Royal Parks Half Marathon on 13th October #London Check out my JustGiving page and please donate if you can. Thank you! justgiving.com/fundraising/gi…

#Myeloma Paper of the Day: Study of impact of daratumumab on collection & engraftment in myeloma patients undergoing stem cell mobilization w/ G-CSF + plerixafor shows daratumumab does not impair HSC collection nor post-ASCT hematopoietic recovery: pubmed.ncbi.nlm.nih.gov/39367227/. #mmsm

#Scotland 🏴󠁧󠁢󠁳󠁣󠁴󠁿

#AcademicTwitter The Creative Process!😂 #phdlife #phdvoice

I'm thrilled to share our case report on a rare cutaneous manifestation in a patient with multiple myeloma. If you're fascinated by medicine, give it a read! Well done! Mattia D’Agostino British Journal of Haematology | Wiley Online Library onlinelibrary.wiley.com/doi/10.1111/bj…

Thrilled to have participated at #Under40inHematology! It was a fantastic chance to connect with young Italian colleagues and expand our network. The environment was, as always, incredibly inspiring and full of stimulating discussions.

#ASH24 #mmsm ASH 24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702 This is a nice important analysis of the importance of 24-hr urine as a response assessment Rahul Banerjee, MD, FACP

CONGRESS | #ASH24 | PRESENTATION Luca Bertamini @erasmusmcblood presents results from a circulating tumor cell sub-study of the phase III PERSEUS trial. High circulating tumor cells were associated with a worse prognosis in patients with NDMM. The addition of daratumumab to VRd

CONGRESS | #EHA2025 | Evangelos Terpos University of Athens shares the latest update to the EHA-EMN clinical practice guidelines for diagnosis, treatment, and follow-up. Key updates include new guidelines on defining high-risk disease, examinations upon diagnosis, monitoring for SMM,

CONGRESS | #EHA2025 | Francesca Gay Università di Torino presents the long-term follow-up from the phase II FORTE trial of carfilzomib induction, consolidation, and maintenance ± ASCT. KRd with ASCT led to a median PFS 99 mo and 75% 8-year OS rate. The PFS benefit was observed across patient

It’s truly exciting to have contributed to the long-term follow-up analysis of the phase II FORTE trial, and to see the results presented by my mentor. Grateful for the opportunity and proud to be part of my research group. #EHA2025 #FORTE #MultipleMyeloma

Happy to celebrate this important achievement by my friend @R_Enomis in the field of MCL. ❤️ Excellent work! 💪